
    
      The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics
      profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following
      multiple-dose administration of the two different dosing regimens that are being evaluated in
      the Phase 3 RMS studies.
    
  